MD2Me - Texting to Promote Chronic Disease Management
TAHLC - Texting to Promote Adolescent Health Liaisons and Chronic Disease Management
Lead Sponsor: Huang, Jeannie, M.D.
Collaborator: University of California, San Diego
|Source||Huang, Jeannie, M.D.|
UCSD researchers are conducting a study aimed to develop and evaluate a chronic disease self management web and text message based program on health-related self-efficacy and frequency of adolescent-conducted healthcare interactions. We hypothesize that users of the program will demonstrate greater gains between baseline and 8 month measures of health related self-efficacy and adolescent-conducted healthcare interactions as compared to the usual care comparison group.
The MD2Me study (or also known as TAHLC), sponsored by the National Institutes of Health is a 2-year randomized controlled trial to develop and test a text message and Internet based intervention among adolescents and young adults with cystic fibrosis, type 1 diabetes, or inflammatory bowel disease. Adolescents and young adults have been a difficult population to engage in healthcare. It is estimated that 1 in 5 adolescents do not get the healthcare they need. Interventions must address how the healthcare system can engage adolescents with chronic disease and provide opportunities to discuss health-related matters and improve disease outcomes.
This study will help fill multiple gaps in the literature by exploring the utility of a push AND pull SMS texting-based application for chronic disease management among youth. Based on social cognitive theory, the intervention will use accessible technology to promote disease management among adolescents with chronic disease as they transition to adult care. The popularity and usage of SMS already demonstrated by adolescents suggests notable promise for the SMS-based TAHLC program to promote chronic disease self-management and healthcare engagement with substantial positive impacts on health among youth with chronic disease.
|Start Date||October 2009|
|Completion Date||March 2012|
|Primary Completion Date||March 2012|
Intervention Type: Behavioral
Intervention Name: MD2ME
Description: The goals of the MD2Me intervention include increasing disease self-efficacy, disease knowledge, and the ability to control one's disease independently. The intervention includes an 8-week web program with weekly behavioral skills, topics on how to navigate the healthcare system, lifestyle tips, a Discussion Board, and text messages.
Arm Group Label: SMS and Internet
Inclusion Criteria: - ages 14 - 22 years - have cystic fibrosis, type 1 diabetes, or inflammatory bowel disease for at least 6 months - have access to the internet - speak English - has a parent that speaks English or Spanish (if primary participant is under 18) - willingness to attend assessment visits Exclusion Criteria: - pregnant or have children - have a history of substance abuse or other psychiatric disorder that would impair compliance with study protocol
- ages 14 - 22 years
- have cystic fibrosis, type 1 diabetes, or inflammatory bowel disease for at least 6 months
- have access to the internet
- speak English
- has a parent that speaks English or Spanish (if primary participant is under 18)
- willingness to attend assessment visits
- pregnant or have children
- have a history of substance abuse or other psychiatric disorder that would impair compliance with study protocol
Minimum Age: 14 Years
Maximum Age: 22 Years
Healthy Volunteers: No
|Has Expanded Access||No|
|Number Of Arms||2|
Label: SMS and Internet
Description: The SMS and Internet group will receive information, tips, strategies, and questions related to the self management of chronic disease (cystic fibrosis, inflammatory bowel disease, or type 1 diabetes) on a web-based program and via SMS messages.
Type: No Intervention
Description: The Control group will receive monthly tip sheets on various health topics for adolescents and young adults.
|Study Design Info||
Intervention Model: Parallel Assignment
Primary Purpose: Supportive Care
Masking: None (Open Label)